Literature DB >> 16579629

Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.

Hamid Mirzaei1, Jeremy L Schieler, Jean-Christophe Rochet, Fred Regnier.   

Abstract

Parkinson's disease is a movement disorder that results from a loss of dopaminergic neurons in the substantia nigra. The disease is characterized by mitochondrial dysfunction, oxidative stress, and the presence of "Lewy body" inclusions enriched with aggregated forms of alpha-synuclein, a presynaptic protein. Although alpha-synuclein is modified at various sites in Lewy bodies, it is unclear how sequence-specific posttranslational modifications modulate the aggregation of the protein in oxidatively stressed neurons. To begin to address this problem, we developed an affinity pull-down/mass spectrometry method to characterize the primary structure of histidine-tagged alpha-synuclein isolated from catecholaminergic neurons. Using this method, we mapped posttranslational modifications of alpha-synuclein from untreated neurons and neurons exposed to rotenone, an inhibitor of mitochondrial complex I. Various posttranslational modifications suggestive of oxidative damage or repair were identified in a region comprising a 20-residue stretch in the C-terminal part of the protein. The results indicate that alpha-synuclein is subject to discrete posttranslational modifications in neurons with impaired mitochondrial function. Our affinity pull-down/mass spectrometry method is a useful tool to examine how specific modifications of alpha-synuclein contribute to neurologic disorders such as Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16579629     DOI: 10.1021/ac051978n

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  22 in total

1.  Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry.

Authors:  Camelia Vlad; Kathrin Lindner; Christiaan Karreman; Stefan Schildknecht; Marcel Leist; Nick Tomczyk; John Rontree; James Langridge; Karin Danzer; Thomas Ciossek; Alina Petre; Michael L Gross; Bastian Hengerer; Michael Przybylski
Journal:  Chembiochem       Date:  2011-11-07       Impact factor: 3.164

Review 2.  Agrochemicals, α-synuclein, and Parkinson's disease.

Authors:  Blanca A Silva; Leonid Breydo; Anthony L Fink; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-08-30       Impact factor: 5.590

3.  Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson׳s disease.

Authors:  Katherine E Strathearn; Gad G Yousef; Mary H Grace; Susan L Roy; Mitali A Tambe; Mario G Ferruzzi; Qing-Li Wu; James E Simon; Mary Ann Lila; Jean-Christophe Rochet
Journal:  Brain Res       Date:  2014-02-03       Impact factor: 3.252

4.  Affinity enrichment for mass spectrometry: improving the yield of low abundance biomarkers.

Authors:  Brianna Kim; Robyn Araujo; Marissa Howard; Ruben Magni; Lance A Liotta; Alessandra Luchini
Journal:  Expert Rev Proteomics       Date:  2018-03-22       Impact factor: 3.940

5.  Rotenone inhibits autophagic flux prior to inducing cell death.

Authors:  Burton J Mader; Violetta N Pivtoraiko; Hilary M Flippo; Barbara J Klocke; Kevin A Roth; Leandra R Mangieri; John J Shacka
Journal:  ACS Chem Neurosci       Date:  2012-09-13       Impact factor: 4.418

Review 6.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

7.  Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults.

Authors:  Fang Liu; Jagadish Hindupur; Jamie L Nguyen; Katie J Ruf; Junyi Zhu; Jeremy L Schieler; Connie C Bonham; Karl V Wood; V Jo Davisson; Jean-Christophe Rochet
Journal:  Free Radic Biol Med       Date:  2008-04-11       Impact factor: 7.376

8.  Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Phil Hyu Lee; Anthony Adame; Chandra Inglis; Michael Mante; Edward Rockenstein; Nadia Stefanova; Gregor K Wenning; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2009-09       Impact factor: 4.164

9.  Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.

Authors:  Li Chen; Magali Periquet; Xu Wang; Alessandro Negro; Pamela J McLean; Bradley T Hyman; Mel B Feany
Journal:  J Clin Invest       Date:  2009-10-12       Impact factor: 14.808

10.  Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.

Authors:  Kelly J Inglis; David Chereau; Elizabeth F Brigham; San-San Chiou; Susanne Schöbel; Normand L Frigon; Mei Yu; Russell J Caccavello; Seth Nelson; Ruth Motter; Sarah Wright; David Chian; Pamela Santiago; Ferdie Soriano; Carla Ramos; Kyle Powell; Jason M Goldstein; Michael Babcock; Ted Yednock; Frederique Bard; Guriqbal S Basi; Hing Sham; Tamie J Chilcote; Lisa McConlogue; Irene Griswold-Prenner; John P Anderson
Journal:  J Biol Chem       Date:  2008-11-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.